This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Joseph Menzin, PhD; Graham A. Colditz, MBBS, DrPH; Meredith M. Regan; Randel E. Richner, RN, MPH; Gerry Oster, PhD

Arch Intern Med. 1995;155(7):757-764.

Abstract
Background
Enoxaparin sodium, a low-molecular-weight heparin, was recently approved for use in the United States to prevent deep-vein thrombosis after total hip replacement surgery. Its cost-effectiveness relative to prophylaxis with low-dose warfarin sodium is unknown.

Methods
A decision-analytic model was developed to compare two strategies of prophylaxis for deep-vein thrombosis with a strategy of not using prophylaxis in a hypothetical cohort of 10 000 patients undergoing total hip replacement surgery. For each of these strategies, we estimated the expected number of cases of confirmed deep-vein thrombosis or pulmonary embolism, the expected number of thromboembolic deaths, and the expected costs of venous thromboembolic care, including prophylaxis, diagnosis, and treatment. Data were drawn primarily from the published literature.

Results
Compared with no prophylaxis, the use of low-dose warfarin would be expected to reduce the number of cases of confirmed deep-vein thrombosis from about 1000 (per 10 000 patients) to 420 and the number of thromboembolic deaths from about 250 to 110. Expected costs of care related to deep-vein thrombosis also would be reduced from approximately $530 to $330 per patient. Prophylaxis with enoxaparin would be expected to reduce further the number of cases of confirmed deep-vein thrombosis and the number of thromboembolic deaths (to 250 and 70, respectively) but increase costs of care by approximately $50 per patient. The cost-effectiveness of enoxaparin (relative to low-dose warfarin) is estimated to be approximately $12 000 per death averted.

Conclusion
Although enoxaparin is more costly than low-dose warfarin, its cost-effectiveness in total hip replacement compares favorably with that of other generally accepted medical interventions.

(Arch Intern Med. 1995;155:757-764)

Author Affiliations
From Policy Analysis Inc, Brookline, Mass (Drs Menzin and Oster and Mss Regan and Richner); and Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass (Dr Colditz). Ms Richner is now with SmithKline Beecham Pharmaceuticals, Philadelphia, Pa.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Postdischarge Oral Versus Injectable Anticoagulation Following Major Orthopedic Surgery
Shorr et al.
The Annals of Pharmacotherapy 2008;42:1222-1228.
ABSTRACT | FULL TEXT  

Comparing the Costs, Risks, and Benefits of Competing Strategies for the Primary Prevention of Venous Thromboembolism
Avorn and Winkelmayer
Circulation 2004;110:IV-25-IV-32.
ABSTRACT | FULL TEXT  

Prevention of Venous Thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Geerts et al.
Chest 2004;126:338S-400S.
ABSTRACT | FULL TEXT  

The Economics of Venous Thromboembolism Prophylaxis: A Primer for Clinicians
Davidson et al.
Chest 2003;124 :393S-396S.
ABSTRACT | FULL TEXT  

Survival Impact of Tamoxifen Use for Breast Cancer Risk Reduction: Projections from a Patient-Specific Markov Model
Col et al.
Med Decis Making 2002;22:386-393.
ABSTRACT  

A Meta-Analysis of Thromboembolic Prophylaxis Following Elective Total Hip Arthroplasty
Freedman et al.
JBJS 2000;82:929-929.
ABSTRACT | FULL TEXT  

Risks vs Benefits in Total Joint Surgery
Lotke and Heit
Chest 1999;116:843-845.
FULL TEXT  

Individualizing Therapy to Prevent Long-term Consequences of Estrogen Deficiency in Postmenopausal Women
Col et al.
Arch Intern Med 1999;159:1458-1466.
ABSTRACT | FULL TEXT  

Economic Analysis of Low-Dose Heparin vs the Low-Molecular-Weight Heparin Enoxaparin for Prevention of Venous Thromboembolism After Colorectal Surgery
Etchells et al.
Arch Intern Med 1999;159:1221-1228.
ABSTRACT | FULL TEXT  

Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness Analysis
Gould et al.
ANN INTERN MED 1999;130:789-799.
ABSTRACT | FULL TEXT  

Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism: Current Recommendations
Hull and Pineo
CLIN APPL THROMB HEMOST 1998;4:96-104.
ABSTRACT  

Unfractionated versus low-molecular-weight heparin in the treatment of venous thromboembolism
Bounameaux
Vasc Med 1998;3:41-46.
ABSTRACT  

Low-Molecular-Weight Heparins
Weitz
NEJM 1997;337:688-699.
FULL TEXT  

Subcutaneous Low-Molecular-Weight Heparin vs Warfarin for Prophylaxis of Deep Vein Thrombosis After Hip or Knee Implantation: An Economic Perspective
Hull et al.
Arch Intern Med 1997;157:298-303.
ABSTRACT  

Antithrombotic Strategy After Total Hip Replacement: A Cost-effectiveness Analysis Comparing Prolonged Oral Anticoagulants With Screening for Deep Vein Thrombosis
Sarasin and Bounameaux
Arch Intern Med 1996;156:1661-1668.
ABSTRACT  

Cost-effectiveness of Prophylactic Anticoagulation Prolonged After Hospital Discharge Following General Surgery
Sarasin and Bounameaux
Arch Surg 1996;131:694-697.
ABSTRACT